Abstract: Oil compositions and compositions thereof that can form nanoemulsions or microemulsions are disclosed. Such compositions and compositions thereof can be useful for antimicrobial properties and be used to treat or prevent microbial infections.

Abstract: Compositions and methods for the preparation of nanoemulsion from oils are disclosure. These nanoemulsions can be produced without the addition of exogenous surfactants or emulsifiers and can be useful as carriers for active ingredients.

Abstract: Compositions and methods are provided for incorporating processed oils with high monoacylglyceride (MAG) content into products and food products. Methods are specifically provided for generating high MAG content processed oils.

Abstract: Compositions and methods are provided for incorporating processed oils with high monoacylglyceride (MAG) content into products and food products. Methods are specifically provided for generating high MAG content processed oils.

Abstract: The invention provides modified T-cell receptors referred to herein as “dominant negative ligand-chimeric antigen receptors” (DNL-CARS). The present invention also provides T-cells expressing DNL-CARs such T cells also referred to herein as “DNL-CAR-expressing T cells” or “DNL-CAR T cells. Also provided are “tagged-DNL/CAR-T systems” that direct CAR-T cells to tumor cells previously complexed to the DNL-Tag fusion. Also provided are tagged-DNL-antigen fusion proteins wherein the antigen portion of the fusion proteins recruits the patient's own immune system to neutralize cells tagged with the tagged DNL portion of the fusion protein.

Abstract: Compositions and methods are provided for incorporating processed oils with high monoacylglyceride (MAG) content into products and food products. Methods are specifically provided for generating high MAG content processed oils.

Abstract: The present invention provides a host microorganism with a deletion, disruption or mutation in one or more enzymes of a glycerol dissimilation pathway and a plasmid without an antibiotic resistance gene but carrying one or more genes encoding enzymes involved in glycerol dissimilation, wherein the plasmid is stably maintained by the host microorganism when cultured on glycerol as a carbon source. Such a plasmid maintenance system is beneficial in applications where the presence of an antibiotic resistance gene or the use of antibiotics is either prohibited or problem.

Abstract: The present invention provides non-naturally occurring microorganisms that have been modified to produce isoprene from glycerol. The microorganisms include one of several glycerol dissimilation pathways and one of several isoprene production pathways.

Abstract: The present invention provides a novel biosynthetic pathway for the production of isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol. Further embodiments provide non-naturally occurring microorganism that have been modified to produce isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol and methods of producing isoprene using said microorganism.

Abstract: The present invention provides compositions and methods for the use of oil-containing materials as feedstocks for the production the bioproducts by biofermentation. In one preferred embodiment, surfactants are not used in compositions and the methods of the invention. In one preferred embodiment the oil-containing feedstocks are the by-products of other industrial processes including microbial, plant and animal oil processing.

Abstract: The present invention provides a novel biosynthetic pathway for the production of isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol. Further embodiments provide non-naturally occurring microorganism that have been modified to produce isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol and methods of producing isoprene using said microorganism.

Abstract: The present invention provides a novel biosynthetic pathway for the production of isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol. Further embodiments provide non-naturally occurring microorganism that have been modified to produce isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol and methods of producing isoprene using said microorganism.

Abstract: The present invention provides a novel biosynthetic pathway for the production of isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol. Further embodiments provide non-naturally occurring microorganism that have been modified to produce isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol and methods of producing isoprene using said microorganism.

Abstract: The present invention provides a novel biosynthetic pathway for the production of isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol. Further embodiments provide non-naturally occurring microorganism that have been modified to produce isoprene from 3-methyl-2-buten-1-ol or 2-methyl-3-buten-2-ol and methods of producing isoprene using said microorganism.

Abstract: The present invention features human epidermal receptor (HER) antagonists. These antagonists are polypeptide variants of ligands of HER. The HER ligand polypeptide variants of the invention possess Pan-HER antagonistic properties and can inhibit at least one HER-mediated biological activity of one or more HER subtypes, such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of HER activity is indicated.

Abstract: The present invention relates to IGF-I variants that bind to the Insulin-like Growth Factor Receptor I (IGF-IR) but do not initiate signal transduction and the subsequent metabolic, growth and anti-apoptotic activities associated with this molecule and the progression of cancer. These novel variants act to block the binding of the cognate ligands but do not bind to the insulin receptor.

Abstract: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.

Abstract: The present invention features human epidermal receptor (HER) antagonists. These antagonists are polypeptide variants of ligands of HER. The HER ligand polypeptide variants of the invention possess Pan-HER antagonistic properties and can inhibit at least one HER-mediated biological activity of one or more HER subtypes, such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of HER activity is indicated.

Abstract: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.

Abstract: The present invention relates to a method for the desulfurization of a fossil fuel containing one or more organosulfur compounds. In one embodiment, the method comprises the steps of (1) contacting the fossil fuel with a biocatalyst capable of converting the organosulfur compound to an oxyorganosulfur compound which is separable from the fossil fuel; and (2) separating the oxyorganosulfur compound from the fossil fuel. The oxyorganosulfur compound can then be isolated, discarded or further processed, for example, via desulfurization by a biocatalyzed process or an abiotic process, such as hydrodesulfurization.